View Older Stories View More Recent Stories
-
Thermo Fisher to acquire Sanofi's New Jersey manufacturing site
-
Adagene (ADAG) announces up to $25 million strategic investment from Sanofi (SNY)
-
Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies
-
Sanofi (SAN:FP) (SNY) PT Lowered to EUR8.40 at BofA Securities
-
Sanofi (SNY) Prices EUR 1.5B in Notes Offerings
-
Bernstein: 'Why Are We Bullish on Sanofi (SAN:FP) (SNY) ?'
-
Stifel Reiterates Buy Rating on Nurix (NRIX)
-
Leerink Partners Reiterates Market Perform Rating on Nurix (NRIX)
-
Citi Reiterates Sell Rating on Blueprint Medicines (BPMC) As Co is Acquired
-
Sanofi (SNY) Exercises License Extension Option to Nurix’s (NRIX) STAT6 Program
-
Sanofi to acquire Blueprint Medicines, $129 per share
-
Jefferies: These 3 catalysts could drive upside in Sanofi shares
-
TD Cowen Reiterates Hold Rating on Sanofi (SNY)
-
Sanofi (SNY) opens $130 million NJ offices
-
Jefferies Downgrades Vigil Neuroscience Inc (VIGL) to Hold
-
Sanofi (SNY) to acquire Vigil Neuroscience
-
Sanofi (SNY) announces plans to invest $20 billion in the U.S. through 2030
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
Sanofi (SNY) Tops Q1 EPS by 12c; reaffirms guidance
-
Sanofi Q1 earnings preview: analysts focus on pipeline, US policy risks
-
BNP Paribas Exane Starts Sanofi (SAN:FP) (SNY) at Outperform
-
Pharma stocks slide after Trump signals tariffs on sector
-
FDA approves Sanofi’s (SNY) hemophilia treatment Qfitlia
-
Regeneron (REGN, Sanofi (SNY): Dupixent Approved as the First-ever Biologic Medicine in Japan for Patients with COPD
-
Goldman Sachs Starts Sanofi (SNY) at Neutral
-
Goldman Sachs Starts Sanofi (SAN:FP) (SNY) at Neutral
-
Sanofi (SNY) adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
-
Expect the beat-and-raise path to continue for this European pharma name
-
Sanofi's Rilzabrutinib gets orphan designation by FDA for AIHA treatment
-
Sanofi (SAN:FP) (SNY) PT Raised to EUR6.50 at CFRA
-
Deutsche Bank Upgrades Sanofi (SAN:FP) (SNY) to Hold
-
Sanofi (SAN:FP) (SNY) PT Raised to EUR120 at Leerink Partners
-
Sanofi (SNY) Tops Q4 EPS by 53c; offers outlook
-
Sanofi (SNY 1700 contracts of February 50 puts trade
-
TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
Sanofi (SNY) Appoints Jean-Paul Kress to its Board
-
TD Cowen Reiterates Hold Rating on Sanofi-Aventis (SNY) as 'Duvakitug Shows Strong Topline Data'
-
Teva (TEVA) and Sanofi (SNY) Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
-
Could Moderna stock be due for rally in 2025? Jefferies weighs in
-
Jefferies Reiterates Buy Rating on Sanofi (SAN:FP) (SNY), 'Top Pick Into 2025'
-
Sanofi (SNY) Plans To Change Hospital Drug-discount Program - WSJ
-
Sanofi (SNY) Tops Q3 EPS by 88c; offers guidance
-
Pai Partners Said To Raise Offer By EUR200M For Sanofi's (SNY) OTC Unit - Bloomberg
-
CD&R Is Said To Plan Measures To Ease Concerns On Sanofi (SNY) Deal - Bloomberg
-
Sanofi (SNY) confirms discussions to sell a controlling stake in Opella to CD&R
-
CD&R Said To Near EUR15b Deal For Sanofi’s (SNY) Consumer Health Unit - Bloomberg
-
Regeneron (REGN): Dupixent Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease
-
Sanofi (SNY) Said to Get Binding Bids From CR&R, PAI for Consumer Arm - Bloomberg
-
Ventyx Biosciences (VTYX) Announces $27M Strategic Investment from Sanofi (SNY)
